Some authors even postulated that hypertensive patients treated with angiotensin II type 1 receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEis), which up-regulate ACE2, could be at higher risk for increased COVID-19 severity, and replacement with alternative pharmacological treatments was advocated [43–45]. The gene discussed is ACE2; the disease is COVID-19.